SLRN Acelyrin
- 3.410
- 0.0000.00%
Acelyrin News
ACELYRIN Is Maintained at Overweight by Wells Fargo
Wells Fargo Maintains Overweight on Acelyrin, Lowers Price Target to $13
Macy's, Dave & Buster's, Bausch + Lomb And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
Piper Sandler Maintains Acelyrin(SLRN.US) With Buy Rating, Maintains Target Price $20
A Quick Look at Today's Ratings for Acelyrin(SLRN.US), With a Forecast Between $6 to $20
Acelyrin Shares Are Trading Lower After the Company Announced Its Phase 2b/3 Study of Izokibep Did Not Meet Its Primary Endpoint, With Secondary Endpoints Also Failing to Achieve Statistical Significance.
Express News | Acelyrin Shares Are Trading Lower After the Company Announced Its Phase 2b/3 Study of Izokibep Did Not Meet Its Primary Endpoint, With Secondary Endpoints Also Failing to Achieve Statistical Significance
Express News | ACELYRIN Inc Shares Down 16.5% Premarket After Co's Eye Drug Fails in Study, CFO Resigns
ACELYRIN, INC. (SLRN) Receives a Buy From Piper Sandler
Express News | HC Wainwright & Co. Reiterates Neutral on Acelyrin, Maintains $8 Price Target
Acelyrin Analyst Ratings
Optimistic Outlook for ACELYRIN as Focus Shifts to Promising TED Treatment
Hold Rating for ACELYRIN, INC. Amid Izokibep Trial Setback and Focus on Lonigutamab Development
Express News | ACELYRIN Inc : Jefferies Cuts Target Price to $8 From $14
Acelyrin Says Uveitis Treatment Trial Fails to Meet Primary Endpoint; Shares Fall After Hours
Acelyrin Finance Chief Gil Labrucherie to Exit
ACELYRIN Faces CFO Resignation and Trial Setback
Express News | ACELYRIN Inc - Gil M. Labrucherie to Resign as CFO and Cbo of ACELYRIN Effective Jan 2, 2025
Acelyrin Announces Izokibep Trial Did Not Meet Primary Endpoint
Express News | ACELYRIN Inc - Company Projects Cash Runway to Mid-2027
No Data